RxDoctor Payments Data

Yaohan Lam, MD

Dermatology · Oklahoma City, OKNPI 1285954305

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $74,475 of the $87,756 with a category attached, or 84.9%. 27 manufacturers reported payments, led by Lilly USA, LLC at 50.7% of the total. 2025 is the largest year on record at $33,352, more than ten times the $599 reported in 2019. Among dermatology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,756in general payments, 2019–2025

Across 536 payments — averaging $163.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$44K
  • Incyte Corporation$37K
  • LEO Pharma Inc.$935
  • Novartis$860
  • Regeneron Healthcare Solutions, Inc.$693
  • Sanofi$616
  • plus $3K from 21 others
$1,061,780in research payments, 2019–2025

Across 537 payments — averaging $1977.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$329K
  • Incyte Corporation$239K
  • Pfizer$121K
  • Eli Lilly$100K
  • Janssen Research & Development, LLC$77K
  • Dermavant Sciences, Inc.$56K
  • plus $140K from 6 others

What the payments were for

  • Speaking & faculty fees$74,47585%
  • Travel & lodging$3,3824%
  • Food & beverage$9,44011%
  • Education$4591%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,756 in reported general payments places this provider in the 95th percentile of 114 dermatology providers in Oklahoma.

See all dermatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$213,571
Medicare patients
854
Services billed
3,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate160$7,383
Tacrolimus27$3,537
Fluorouracil51$3,412
Doxycycline Hyclate92$2,612
Ketoconazole168$2,510
Calcipotriene15$1,860
Triamcinolone Acetonide93$1,255
Clindamycin Phosphate19$899
Gabapentin48$695
Dapsone17$652
Betamethasone Dipropionate16$650
Hydrocortisone81$507
ValacyclovirValacyclovir Hcl11$333
Mupirocin21$261
Fluconazole16$166

Paid to pharmacies, not to this prescriber.

Other dermatology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →